Elicera Therapeutics’ CARMA Study Unveils Striking 91% Tumor Response in Relapsed/Refractory B-cell Lymphoma, Including Prior CAR T-Cell Failures

August 17, 2026

Elicera Therapeutics Sweden

Overview

Elicera Therapeutics has concluded patient enrollment for the Phase I segment of its CARMA study, evaluating ELC-301 in patients with relapsed or refractory B-cell lymphoma. Interim efficacy data from 11 patients reveal a remarkable 91% objective tumor response rate and 100% disease control, with 55% achieving a complete metabolic response. Critically, these promising outcomes extended to patients who had previously failed approved CAR T-cell therapies, highlighting a significant advancement for individuals with extremely limited treatment options.

In Depth

Background

B-cell lymphoma represents a prevalent form of hematological malignancy. While conventional chemotherapy and targeted therapies are effective for many patients, those facing relapsed or refractory disease confront severely constrained treatment options. Approved CAR T-cell therapies have indeed revolutionized care for these patients, yet a significant subset either experiences disease recurrence post-treatment or exhibits no response. This critical unmet medical need underscores the urgency for novel CAR T-cell therapies capable of demonstrating efficacy in patients previously treated with existing options. Elicera’s proprietary iTANK platform is specifically engineered to surmount the inherent limitations of current CAR T-cell therapies, aiming to broaden their therapeutic reach to a wider patient demographic.

Key Findings

Elicera Therapeutics has announced the successful completion of patient enrollment and treatment for the Phase I segment of its CARMA study. This trial evaluates ELC-301 in patients grappling with relapsed or refractory B-cell lymphoma. Interim efficacy data, derived from the 11 patients assessed to date, are profoundly encouraging: the study observed a 100% disease control rate and an impressive 91% objective tumor response rate, with 55% of patients achieving a complete metabolic response. A standout discovery is the documentation of robust tumor responses even among patients who had previously undergone and failed approved CAR T-cell therapies, a population with historically bleak prognoses.

Technical / Clinical Details

The CARMA study is actively evaluating ELC-301, a cutting-edge CAR T-cell therapy engineered by Elicera Therapeutics. ELC-301 is a CD20-targeting CAR T-cell, meticulously designed utilizing the company’s proprietary iTANK platform—a next-generation CAR T-cell technology. The iTANK platform’s innovative mechanism is centered on boosting CAR T-cell persistence and amplifying anti-tumor activity through the integration of a novel stimulatory factor. Although the primary aim of this Phase I investigation was to ascertain the safety and tolerability profile of ELC-301, secondary endpoints encompassed comprehensive efficacy assessments. The compelling efficacy data reported indicate that ELC-301 holds substantial promise to deliver therapeutic advantages for patients with relapsed/refractory B-cell lymphoma, notably extending to those who have exhausted prior CAR T-cell treatment options. Achieving a complete metabolic response rate of 55% within such a challenging patient cohort signifies a profoundly optimistic harbinger for its continued development.

Strategic Significance & Outlook

The successful conclusion of the CARMA study’s Phase I component, coupled with these highly promising efficacy data, establishes a robust foundation for ELC-301’s ongoing clinical advancement. Elicera Therapeutics is poised to capitalize on these compelling results, aiming to swiftly transition into larger, pivotal Phase II clinical trials. The demonstrated responses in patients previously refractory to existing treatments are especially impactful, hinting at ELC-301’s potential to fundamentally shift the current therapeutic paradigm for B-cell lymphoma. Should ELC-301 maintain its efficacy and favorable safety profile in subsequent trials, it would emerge as a vital new treatment modality for patients grappling with relapsed/refractory B-cell lymphoma. This breakthrough marks a significant evolutionary milestone for CAR T-cell therapies, particularly in the challenging landscape of difficult-to-treat hematological cancers.

Source: https://www.elicera.com/press-releases/elicera-therapeutics-last-patient-treated-in-the-phase-i-part-of-the-carma-study—tumor-responses-in-10-of-11-patients-evaluated-to-date

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.